OBJECTIVE： To explore the effects of Lujiao zhuanggu capsules on reproductive endocrine hormone and bone metabolism in patients with postmenopausal osteoprosis （PMOP）. METHODS： 120 patients with PMOP were divided into control group （59 cases） and observation group （61 cases） according to random number table. Control group was given Caltrate D3 tablets， one tablets， tid and Alfacalcidol capsules， 0.50 μg， tid. Observation group was additionally given Lujiao zhuanggu capsules orally， 1.35 g， tid， on the basis of control group. A treatment course lasted for 3 months， and both groups received 2 courses of treatment. The bone mineral density （BMD） of lumbar spine （L1-L4） and femoral neck were compared between 2 groups before treatment， 3， 6 months after treatment. The contents of follicle-stimulating hormone （FSH）， luteinizinghormone （LH）， estradiol （E2）， testosterone （T）， bone gla protein （BGP）， calcitonin （CT） and parathyroid hormone （PTH） were observed in 2 groups by radio immunoassay as well as the occurrence of ADR. RESULTS： 3 patients were withdrewl from observation group and 2 from control group. Before treatment， there was no statistical significance in each index between 2 groups （P＞0.05）. After 3 months of treatment， the levels of FSH， E2， BGP， CT and PTH in observation group were increased significantly and higher than control group， with statistical significance （P＜0.05）. After 6 months of treatment， BMD of lumbar spine （L1-L4） and femoral neck， serum levels of FSH， E2， BGP， CT and PTH were higher than before treatment and （or） after 3 months of treatment， and the observation group was higher than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Lujiao zhuanggu capsules not only regulates the secretion of reproductive hormone endocrine， but also increases BMD and decreases bone transformation.